Top Thought Leaders In Biotech Are Heading To THIS Company
One Biotech Company Has Begun to Capitvate Investors & A New CEO At The Helm Could Be Presenting Near Term Opportunity!
Agenus Inc (NASDAQ:AGEN) Reports Combination Clinical Studies Of Its Anti-CTLA4 And Anti-PD1
Agenus Inc (NASDAQ:AGEN) reported the release of its combination study with its proprietary anti-PD1 (AGEN2034) and anti-CTLA4 (AGEN1884) antibodies. The Phase 1/2 clinical study introduced in December 2017 and registration into the initial cohort has been fast completed.